Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Basilea Pharmaceutica AG

Basilea is a commercial stage biopharmaceutical R&D company focused on developing products that address medical challenges in the therapeutic area of anti-infectives.

Basilea

Basilea Pharmaceutica | 17,375 followers on LinkedIn. For the benefit of patients  | Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections.

Procurement Manager Technical Operations at BASILEA

Olf Thomas Krumm

Gerrit Hauck

Senior Quality Assurance Specialist

Frédéric Lasserre

Chairman Of The Board at RocketVax

Jeanette Wood

Basilea Pharmaceutica

We are #hiring ! Please click on the job advertisement below for further information.

" #AMR is important today, but the bigger issue is what could happen in the future." In a recent interview with PharmaBoardroom , our CEO David Veitch shared his insights into Basilea's strategic vision to become a global leader in the #antifungal and #antibacterial space. Read the whole story: https://lnkd.in/eHTGub_k

We look forward to tomorrow's panel discussion organized by Life Science Zurich Young Scientist Network ! Our Chief Scientific Officer, Dr. Laurenz Kellenberger, will join the conversation on “From Labs To Legislation: Breaking Antimicrobial Resistance” at University of Zurich , along with three other experts in the field. If you are in Zurich and interested in #AMR , don't miss it!

We are very happy about partnering with the Biomedical Advanced Research and Development Authority (BARDA) , for the development of new #antifungals and #antibacterials . This will help us to further address the critical medical needs of patients. 🎥 In this interview with BiotechTV , our CEO David Veitch , describes why this news is a confirmation of the strength of Basilea's portfolio and business model.

Secondary infections caused by drug-resistant fungi can complicate patient treatment during a public health emergency, which is why developing new therapeutic options is critical. In support of Fungal Disease Awareness Week, we are pleased to announce our partnership with Basilea Pharmaceutica to advance the development of two antifungal candidates: Fosmanogepix, a broad-spectrum antifungal, and BAL2062, a candidate intended to treat invasive Aspergillus infections. Learn more about our first contract to develop antifungal therapeutics: https://ow.ly/cqbX50TqqeW

Biomedical Advanced Research and Development Authority (BARDA)

Basilea receives BARDA funding to advance development of two #new #antifungals Today we announced that Basilea was awarded an Other Transaction Agreement (OTA) by the Biomedical Advanced Research and Development Authority (BARDA) to support the development of first-in-class antifungals and #antibacterials . Basilea received an initial funding of USD 29 million for the development of its clinical stage antifungals, fosmanogepix and BAL2062, with an option for more funding to develop Basilea’s portfolio. David Veitch , CEO of #BasileaPharmaceutica , said: “Basilea has been working with BARDA since 2013. In continuing this partnership through an OTA, we will be leveraging our strong portfolio and the capabilities of our organization to develop urgently needed novel antifungals and antibacterials.” Find more information in our #PressRelease : https://lnkd.in/eX8dp-dK

COM:BASILEA